Compare Invesco WilderHill Clean Energy ETF (PBW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs Tango Therapeutics Inc. — how do they compare? Invesco WilderHill Clean Energy ETF trades at $25.7 (market cap $314.02M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 11.9× Invesco WilderHill Clean Energy ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco WilderHill Clean Energy ETF for 47 Days and Tango Therapeutics Inc. for 0 Days on average.
| PBW | TNGX | |
|---|---|---|
Market Cap | $314.02M | $3.74B |
Volume | 395,641 | 3,438,781 |
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $32.90 |
52-Week Low | $25.77 | $7.50 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Invesco WilderHill Clean Energy ETF (PBW) trades at $27.33, down 0.33% on the day, with a bearish technical signal driven by moving averages. Key financial ratios such as P/E and P/S are not applicable for this ETF. Recent news highlights institutional selling, with IFP Advisors cutting its stake by 96.3% in Q2 2026 (SEC filing, September 18, 2026).
The outlook is cautious due to technical weakness and institutional outflows. Opportunities lie in the clean energy theme amid global investment, but risks include high volatility and concentrated portfolio strategy. The ETF's performance is tied to sector sentiment rather than traditional corporate fundamentals.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
